Our portfolio company Unnatural Products has closed a $45 million Series B financing to advance its platform for a new class of medicines built on synthetic macrocyclic peptides. The round was led by The Venture Collective (TVC), with participation from argenx, Droia Ventures, Merck Global Health Innovation Fund, ARTIS, and First Spark Ventures.
Macrocyclic peptides represent an emerging therapeutic modality that combines the precision of biologics with the delivery advantages of small molecules. This opens new possibilities for targeting complex proteins historically considered "undruggable" and for developing oral solutions in indications currently limited to injectables. The proceeds will support continued development of Unnatural Products' discovery platform and advance its pipeline across cardiometabolic, inflammatory, and immunological diseases.
This milestone follows the company's recently announced collaboration with Novartis, which includes up to $100 million upfront and pre-IND milestones, along with $1.7 billion in potential milestones and royalties to develop macrocyclic peptide therapeutics for cardiovascular targets.
Congrats to the Unnatural Products team on this achievement, and we look forward to supporting them as they build toward the next generation of precision therapeutics.
Read the full press release here.
Macrocyclic peptides represent an emerging therapeutic modality that combines the precision of biologics with the delivery advantages of small molecules. This opens new possibilities for targeting complex proteins historically considered "undruggable" and for developing oral solutions in indications currently limited to injectables. The proceeds will support continued development of Unnatural Products' discovery platform and advance its pipeline across cardiometabolic, inflammatory, and immunological diseases.
This milestone follows the company's recently announced collaboration with Novartis, which includes up to $100 million upfront and pre-IND milestones, along with $1.7 billion in potential milestones and royalties to develop macrocyclic peptide therapeutics for cardiovascular targets.
Congrats to the Unnatural Products team on this achievement, and we look forward to supporting them as they build toward the next generation of precision therapeutics.
Read the full press release here.